Clinical trials: Resistant Major Depressive Disorder
Major Depressive Disorder
Do Antidepressants Induce Metabolic Syndromes METADAP Study
Since antidepressants and antipsychotics have common receptorial mechanisms of action (H1 antagonism, 5HT2 antagonism), the impact of antidepressants in terms of metabolic syndromes is a matter of concern.
- Trial name
- METADAP (NCT00526383)
- Testing
- Tricyclic antidepressants
- Where
- France
- Volunteers
- 624 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder
Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder
This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT04216095
- Testing
- Electroconvulsive Therapy (n=30), Magnetic Seizure Therapy (n=30)
- Volunteers
- 60 people
- Sponsor
- Tanta University
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Therapy Resistant Major Depression
Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression
tDCS applies a small amount of direct electric current (DC) to the brain by means of two electrodes: the one is an active electrode, localized on the effective site, and the other is a reference electrode, localized on some…
- Trial name
- NCT00667680
- Testing
- Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Major Depressive Disorder
Closed-Loop Deep Brain Stimulation for Major Depression
Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry.
- Trial name
- PReSiDio (NCT04004169)
- Testing
- Stimulation-ON, Stimulation-OFF, Stimulation-ON Active Control
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Andrew Krystal
Depressive Disorder, Treatment-Resistant
Biomarkers of Theta Burst Stimulation in Major Depressive Disorder
This study investigates the brain-based biomarkers of treatment response to accelerated theta burst stimulation (aTBS) in patients with Major Depressive Disorder resistant to pharmacological treatment(MDD) in an open label design.
- Trial name
- NCT03626181
- Testing
- Theta Burst Stimulation ( Transcranial Magnetic Stimulation)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Calgary
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
One-Day cTBS Over the Precuneus
The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression.
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
- Trial name
- OcTOPUS (NCT07758010)
- Testing
- Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mclean Hospital
Treatment Resistant Depression
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
The present study has been designed to compare the efficacy and safety of augmentation of SSRIs with Amantadine vs Pramipexole vs the recommended Quetiapine augmentation in Treatment-Resistant Depression (TRD) and correlate the…
- Trial name
- APQ-TRD (NCT04936126)
- Testing
- Quetiapine, Amantadine, Pramipexole
- Where
- India
- Volunteers
- 150 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Major Depressive Disorder
A Double-blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression
The main treatment option for Treatment Resistant Depression is electroconvulsive therapy (ECT) which is often effective but complicated by cognitive side effects, need for anaesthesia and considerable stigma.
- Trial name
- NCT00402220
- Testing
- TMS
- Where
- Australia
- Volunteers
- 67 people
- Sponsor
- Bayside Health
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Major Depressive Disorder, Metabolic Syndrome
Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder
Aim 1 is to study prevalence and 1 year incidence of metabolic syndrome in major depressive disorder and factors correlation. Aim 2 is to study prevalence and 1 year incidence of thyroid dysfunction in major depressive disorder…
- Conditions
- Major Depressive Disorder, Metabolic Syndrome, Thyroid Dysfunction
- Trial name
- NCT01682785
- Volunteers
- 140 people
- Sponsor
- Chiang Mai University
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Major
VA Aripiprazole vs Esketamine for Treatment Resistant Depression
This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs.
- Trial name
- VAST-D II (NCT05554627)
- Testing
- Esketamine, Aripiprazole
- Where
- 26 sites in United States
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Depression, Treatment Resistant Depression
The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder
The primary goals of this proof of concept clinical trial are to determine the effectiveness, safety and tolerability of oral FMT in adults with Treatment Resistant Depression (TRD).
- Trial name
- NCT04805879
- Testing
- FMT oral Capsules
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- University of Calgary
Major Depressive Disorder
High Dose Accelerated iTBS for Depression
This trial will compare active intermittent theta burst stimulation (iTBS) rTMS in an accelerated treatment schedule (8 treatment sessions per day for 5 days) to a placebo control.
- Trial name
- NCT04255784
- Testing
- Active iTBS
- Where
- 2 sites in Canada
- Volunteers
- 228 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Treatment-Resistant Depression
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
In this double-blind, randomized, sham-controlled trial, the investigators aimed to examine the effect of accelerated piTBS on suicide risk in a group of treatment-resistant patients with MDD (i.e., TRD), using an extensive…
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Suicide Ideations
- Trial name
- NCT06372834
- Testing
- piTBS being delivered using the Magstim Rapid2 stimulator
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Major Depressive Disorder, Unipolar Depression
RTMS Feasibility Study on Adolescent Depression Stimulation
This is an open-label study, in which all participants receives an active treatment with repetitive transcranial magnetic stimulation (rTMS) according to clinical protocol.
- Conditions
- Major Depressive Disorder, Unipolar Depression, Bipolar Depression
- Trial name
- NCT06126198
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Depressive Disorder, Major, Treatment Resistant Depression
Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent
In this study the investigators will submit patients with treatment resistant depression to deep anesthesia with isoflurane to get 15 minutes of cortical burst suppression on electroencephalogram, once a week for six weeks.
- Conditions
- Depressive Disorder, Major, Treatment Resistant Depression, Depressive Episode
- Trial name
- ISORADAR (NCT04171193)
- Testing
- Isoflurane, Sertraline Pill
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.